使用支持向量机将高级别胶质瘤分类为肿瘤与非肿瘤成分
本研究纳入32例高级别胶质瘤和6例脑转移瘤患者的140次MRI扫描,基于T1加权、FLAIR和动态增强MRI参数训练支持向量机分类器,将强化和非强化病灶区分为肿瘤与非肿瘤成分。分类在强化和非强化区均获得100%敏感度和特异度,成分体积纵向变化与RANO标准相关,5例(16%)患者肿瘤成分体积增加提示进展,且早于RANO评估数月。
要点
- 支持向量机基于T1加权、FLAIR和动态增强MRI参数可将强化和非强化病灶区分为肿瘤与非肿瘤成分。
- 强化和非强化区的分类敏感度和特异度均为100%。
- 5例(16%)患者肿瘤成分体积增加提示进展,早于RANO评估数月。
核心结论
- 本研究提出一种自动分类方法,即基于先进影像的分段RANO标准,能可靠区分高级别胶质瘤的肿瘤与非肿瘤成分。
- 分段RANO标准可能改善治疗反应评估并提供更早的进展提示。
研究设计与样本
- 研究纳入32例高级别胶质瘤和6例脑转移瘤患者的140次MRI扫描。
- 使用支持向量机分类器,基于T1加权、FLAIR和动态增强MRI参数,将强化和非强化病灶区分为肿瘤与非肿瘤成分。
- 分类结果通过训练集的2折交叉验证分析和MR波谱评估。
- 成分体积的纵向变化与RANO标准进行比较。
关键影像表现/征象
- 归一化T1加权值、FLAIR、血浆容量、体积转移常数和团注到达时间参数可区分各成分。
- 7例接受贝伐珠单抗治疗的患者显示向浸润性进展模式的转变。
诊断标准与关键数值
- 在强化和非强化区均获得100%的敏感度和特异度。
- 纵向成分体积变化与RANO标准在27例患者中相关;5例(16%)患者肿瘤成分体积增加提示肿瘤进展。
- 这些变化早于RANO评估数月。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Current imaging assessment of high-grade brain tumors relies on the Response Assessment in Neuro-Oncology criteria, which measure gross volume of enhancing and nonenhancing lesions from conventional MRI sequences. These assessments may fail to reliably distinguish tumor and nontumor. This study aimed to classify enhancing and nonenhancing lesion areas into tumor-versus-nontumor components.
MATERIALS AND METHODS: A total of 140 MRI scans obtained from 32 patients with high-grade gliomas and 6 patients with brain metastases were included. Classification of lesion areas was performed using a support vector machine classifier trained on 4 components: enhancing and nonenhancing, tumor and nontumor, based on T1-weighted, FLAIR, and dynamic-contrast-enhancing MRI parameters. Classification results were evaluated by 2-fold cross-validation analysis of the training set and MR spectroscopy. Longitudinal changes of the component volumes were compared with Response Assessment in Neuro-Oncology criteria.
RESULTS: Normalized T1-weighted values, FLAIR, plasma volume, volume transfer constant, and bolus-arrival-time parameters differentiated components. High sensitivity and specificity (100%) were obtained within the enhancing and nonenhancing areas. Longitudinal changes in component volumes correlated with the Response Assessment in Neuro-Oncology criteria in 27 patients; 5 patients (16%) demonstrated an increase in tumor component volumes indicating tumor progression. These changes preceded Response Assessment in Neuro-Oncology assessments by several months. Seven patients treated with bevacizumab showed a shift to an infiltrative pattern of progression.
CONCLUSIONS: This study proposes an automatic classification method: segmented Response Assessment in Neuro-Oncology criteria based on advanced imaging that reliably differentiates tumor and nontumor components in high-grade gliomas. The segmented Response Assessment in Neuro-Oncology criteria may improve therapy-response assessment and provide earlier indication of progression.
引用
- Blumenthal DT, Artzi M, Liberman G, et al. Classification of High-Grade Glioma into Tumor and Nontumor Components Using Support Vector Machine. AJNR Am J Neuroradiol. 2017. PMID: 28385884. doi:10.3174/ajnr.A5127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。